C. Allgulander

S. Pallanti, D. Baldwin, C. Allgulander, 2012, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Panic disorder is associated with the Val308Iso polymorphism in the hypocretin receptor gene

C. Allgulander, E. Eriksson, L. Westberg, 2011, Psychiatric genetics.

Generalized anxiety disorder: What are we missing?

C. Allgulander, 2006, European Neuropsychopharmacology.

R. Rosmond, C. Allgulander, F. Baghaei, 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Association between a functional polymorphism in the progesterone receptor gene and panic disorder in women

P. Björntorp, R. Rosmond, C. Allgulander, 2004, Psychoneuroendocrinology.

[A nationwide study in primary health care: One out of four patients suffers from anxiety and depression].

C. Allgulander, B. Nilsson, 2003, Lakartidningen.

Addiction on prescribed sedative‐hypnotics

C. Allgulander, 1996 .

Generalized anxiety disorder: raising the expectations of treatment.

D. Sheehan, C. Allgulander, 2002, Psychopharmacology bulletin.

Antecedents of neurosis in a cohort of 30,344 twins in Sweden.

J. Rice, P. Allebeck, C. Allgulander, 1994, Anxiety.

Mental health care in Sweden

C. Allgulander, 2020, Taiwanese Journal of Psychiatry.

Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials*

J. Erickson, C. Allgulander, S. Ball, 2007, Current medical research and opinion.

Regular hypnotic drug treatment in a sample of 32,679 Swedes: associations with somatic and mental health, inpatient psychiatric diagnoses and suicide, derived with automated record‐linkage.

C. Allgulander, P. Näsman, 1991, Psychosomatic medicine.

Recommendations for the Long-Term Treatment of Anxiety Disorders

E. Hollander, M. Pollack, J. Greist, 2003 .

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders

D. Rujescu, E. Hollander, N. Fineberg, 2022, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Anxiety as a risk factor in cardiovascular disease

C. Allgulander, 2016, Current opinion in psychiatry.

Pharmacotherapy of generalized anxiety disorder.

D. Baldwin, C. Allgulander, 2013, Modern trends in pharmacopsychiatry.

Generalized Anxiety Disorder: A Review of Recent Findings

C. Allgulander, 2012 .

Suicide among young men: psychiatric illness, deviant behaviour and substance abuse

P. Allebeck, C. Allgulander, 1990, Acta psychiatrica Scandinavica.

Novel approaches to treatment of generalized anxiety disorder

C. Allgulander, 2010, Current opinion in psychiatry.

Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.

Dan J Stein, C. Allgulander, C. Albarrán, 2012, The Journal of clinical psychiatry.

Pilot study of the adjunct utility of a computer-assisted Diagnostic Interview Schedule (C-DIS) in forensic psychiatric patients.

C. Allgulander, J. Ahlberg, J. R. Tuck, 1996, The Bulletin of the American Academy of Psychiatry and the Law.

Establishing non-inferiority in treatment trials in psychiatry — guidelines from an Expert Consensus Meeting

T. Peters, D. Nutt, H. Wittchen, 2008, Journal of psychopharmacology.

Psychopathology and treatment of 30,344 twins in Sweden. I. The appropriateness of psychoactive drug treatment

J. Rice, C. Allgulander, J. Rice, 1990, Acta psychiatrica Scandinavica.

Editorial: Wine and drug evaluations: lessons on making comparisons of noninferiority

D. Nutt, C. Allgulander, D. Nutt, 2008, Journal of psychopharmacology.

Psychiatric diagnoses and perceived health problems in a sample of working Swedes treated with psychoactive medications.

C. Allgulander, B. Evanoff, 1990, Journal of psychoactive drugs.

History and current status of sedative‐hypnotic drug use and abuse

C. Allgulander, C. Allgulander, 1986, Acta psychiatrica Scandinavica.

Clinical significance of abnormal heterogeneity of transferrin in relation to alcohol consumption.

C. Allgulander, S. Borg, H. Stibler, 2009, Acta medica Scandinavica.

Abnormal microheterogeneity of transferrin in serum and cerebrospinal fluid in alcoholism.

C. Allgulander, S. Borg, H. Stibler, 2009, Acta medica Scandinavica.

HIV infection and psychiatric illness.

C. Allgulander, B. Owe‐Larsson, E. Salamon, 2009, African journal of psychiatry.

Psychiatric caseness is a marker of major depressive episode in general practice

P. Munk-Jørgensen, C. Allgulander, A. Dahl, 2010, Scandinavian journal of primary health care.

Risk of suicide by psychiatric diagnosis in Stockholm County

J. Rice, P. Allebeck, C. Allgulander, 2005, European Archives of Psychiatry and Clinical Neuroscience.

Psychiatric Diagnoses as Predictors of Suicide

P. Allebeck, C. Allgulander, 1990, British Journal of Psychiatry.

Causes of death in a cohort of 50 465 young men – Validity of recorded suicide as underlying cause of death

P. Allebeck, C. Allgulander, L. Henningsohn, 1991, Scandinavian journal of social medicine.

Placebo-Controlled Trial Comparing Intermittent and Continuous Paroxetine in Premenstrual Dysphoric Disorder

M. Landén, C. Allgulander, E. Eriksson, 2007, Neuropsychopharmacology.

Can quality care in psychiatry be purchased

C. Allgulander, 1994 .

Anxiety and cardiovascular disease.

C. Allgulander, S. Davies, 2013, Modern trends in pharmacopsychiatry.

Long‐term prognosis in addiction on sedative and hypnotic drugs analyzed with the Cox regression model

C. Allgulander, L. Ljungberg, L. D. Fisher, 1987, Acta psychiatrica Scandinavica.

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD

Dan J Stein, D. Rujescu, E. Hollander, 2022, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder

Dan J Stein, E. Hollander, D. Nutt, 2003, CNS Spectrums.

Survival analysis (or time to an event analysis), and the Cox regression model ‐ methods for longitudinal psychiatric research

L. Fisher, C. Allgulander, 1986, Acta psychiatrica Scandinavica.

Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder

C. Allgulander, K. Dantendorfer, D. Michelson, 2001, British Journal of Psychiatry.

Frusemide Pharmacokinetics in Patients with Liver Disease

C. Allgulander, B. Beermann, A. Sjögren, 1980, Clinical pharmacokinetics.

Suicide and Psychopathology in 1,537 Patients Dependent on Prescribed Psychoactive Medications: Stockholm, Sweden

P. Allebeck, C. Allgulander, L. Brandt, 1994 .

A 4-6-year follow-up of 50 patients with primary dependence on sedative and hypnotic drugs.

C. Allgulander, S. Borg, B. Vikander, 1984, The American journal of psychiatry.

Genetics and personality traits in patients with social anxiety disorder: A case-control study in South Africa

D. Stein, S. Seedat, J. Moolman-Smook, 2007, European Neuropsychopharmacology.

Manifesto for a European Anxiety Disorders Research Network

J. Vázquez-Barquero, A. Metspalu, N. Fineberg, 2010, European Neuropsychopharmacology.

A possible association between panic disorder and a polymorphism in the preproghrelingene

C. Allgulander, E. Eriksson, S. Dickson, 2013, Psychiatry Research.

A possible association between panic disorder and a polymorphism in the preproghrelin gene

C. Allgulander, E. Eriksson, S. Dickson, 2013 .

Case report: a delirious abstinence syndrome associated with clorazepate (Tranxilen).

C. Allgulander, S. Borg, 1978, The British journal of addiction to alcohol and other drugs.

Psychiatric symptoms and disorders in HIV infected mine workers in South Africa. A retrospective descriptive study of acute first admissions.

C. Allgulander, B. Owe‐Larsson, E. Salamon, 2009, African journal of psychiatry.

Psychiatric symptoms and disorders in HIV infected mine workers in South Africa

C. Allgulander, B. Owe‐Larsson, E. Salamon, 2009 .

Predictors of completed suicide in a cohort of 50,465 young men: role of personality and deviant behaviour.

L. Fisher, P. Allebeck, C. Allgulander, 1988, BMJ.

Sedative-hypnotic and alcohol dependence among psychiatric in-patients.

C. Allgulander, S. Borg, 1978, The British journal of addiction to alcohol and other drugs.

Psychoactive drug use in a general population sample, Sweden: correlates with perceived health, psychiatric diagnoses, and mortality in an automated record-linkage study.

C. Allgulander, 1989, American journal of public health.

Suicide and mortality patterns in anxiety neurosis and depressive neurosis.

C. Allgulander, 1994, Archives of general psychiatry.

Causes of death among 936 elderly patients with 'pure' anxiety neurosis in Stockholm County, Sweden, and in patients with depressive neurosis or both diagnoses.

P. Lavori, C. Allgulander, 1993, Comprehensive psychiatry.

Excess mortality among 3302 patients with 'pure' anxiety neurosis.

P. Lavori, C. Allgulander, 1991, Archives of general psychiatry.

WCA Recommendations for the Long-Term Treatment of Social Phobia

Dan J Stein, E. Hollander, D. Nutt, 2003, CNS Spectrums.

Anti‐anxiety agents: a pharmacoepidemiological review

C. Allgulander, 1999 .

Essential Evidence-Based Psychopharmacology: Evidence-based pharmacotherapy of generalized anxiety disorder

D. Baldwin, C. Allgulander, S. Waldman, 2012 .

Evidence-based pharmacological treatment of generalized anxiety disorder.

D. Baldwin, C. Allgulander, S. Waldman, 2011, The international journal of neuropsychopharmacology.

Prevention of relapse in generalized anxiety disorder by escitalopram treatment.

C. Allgulander, I. Florea, A. Huusom, 2006, The international journal of neuropsychopharmacology.

Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors

C. Allgulander, T. Burt, A. Ravindran, 2005, Acta psychiatrica Scandinavica.

Efficacy of sertraline in a 12-week trial for generalized anxiety disorder.

C. Clary, C. Allgulander, S. Kutcher, 2004, The American journal of psychiatry.

Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder

C. Allgulander, E. Salinas, D. Hackett, 2001, British Journal of Psychiatry.

Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder

C. Allgulander, T. Burt, A. Ravindran, 2005, Human psychopharmacology.

Changes on the Temperament and Character Inventory following Paroxetine Treatment in Patients with GAD.

C. Allgulander, R. Cloninger, 1997 .

Antecedents of anxiety syndromes in a cohort of 50,465 young men in Sweden. A prospective analysis of self‐reported and professionally assessed psychosocial characteristics

P. Allebeck, C. Allgulander, L. Brandt, 1992, Acta psychiatrica Scandinavica.

Victims of criminal homicide in Sweden: a matched case-control study of health and social risk factors among all 1,739 cases during 1978-1994.

C. Allgulander, B. Nilsson, 2000, The American journal of psychiatry.

Psychometric properties of the Swedish version of the Childhood Trauma Questionnaire—Short Form (CTQ-SF)

C. Allgulander, A. Gerdner, 2009, Nordic journal of psychiatry.

WCA Recommendations for the Long-Term Treatment of Panic Disorder

E. Hollander, D. Nutt, M. Pollack, 2003, CNS Spectrums.

Dependence on sedative and hypnotic drugs. A comparative clinical and social study.

C. Allgulander, 1979, Acta psychiatrica Scandinavica. Supplementum.

Antipsychotics in anxiety disorders: An oxymoron or a reflection of non-adequate nomenclature?

J. Zohar, C. Allgulander, 2011, European Neuropsychopharmacology.

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine

Jun Zhang, G. Emilien, U. Lepola, 2004, Human psychopharmacology.

Generalized anxiety disorder: between now and DSM-V.

C. Allgulander, 2009, The Psychiatric clinics of North America.

A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder

J. Erickson, M. Detke, D. Nutt, 2008, Journal of psychopharmacology.

Poster 189: Duloxetine as an Effective Treatment for Improving Painful Physical Symptoms and Functioning Associated With Generalized Anxiety Disorder

J. Erickson, C. Allgulander, S. Ball, 2007 .

Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians.

J. Erickson, E. Dunayevich, M. Detke, 2007, Primary care companion to the Journal of clinical psychiatry.

Changes on the Temperament and Character Inventory after paroxetine treatment in volunteers with generalized anxiety disorder.

C. Robert Cloninger, C. Allgulander, T. Przybeck, 1998, Psychopharmacology bulletin.

Psychoactive DrugUseina General Population Sample, Sweden: Correlates withPerceived Health, Psychiatric Diagnoses, andMortality inan Automated Record-Linkage Study

C. Allgulander, 1989 .

Childhood trauma in adults with social anxiety disorder and panic disorder: a cross-national study.

D. Stein, S. Seedat, C. Allgulander, 2011, African journal of psychiatry.

Psychopathology and treatment of 30,344 twins in Sweden. II. Heritability estimates of psychiatric diagnosis and treatment in 12,884 twin pairs

J. Rice, C. Allgulander, J. Rice, 1991, Acta psychiatrica Scandinavica.

Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity

C. Allgulander, B. Bandelow, D. Wajsbrot, 2019, International clinical psychopharmacology.

Implications of pain in generalized anxiety disorder: efficacy of duloxetine.

J. Erickson, J. Endicott, J. Russell, 2008, Primary care companion to the Journal of clinical psychiatry.

P. Auquier, C. Allgulander, M. Toumi, 2007, Current medical research and opinion.

Absence of the Arg441His polymorphism in the tryptophan hydroxylase 2 gene in adults with anxiety disorders and depression

C. Allgulander, I. Skoog, D. Gustafson, 2007, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.

Long-term treatment strategies in anxiety disorders.

D. Nutt, R. Hirschfeld, C. Allgulander, 2002, Psychopharmacology bulletin.

Practice guideline for the treatment of patients with schizophrenia

Julie Kreyenbuhl, Jeffrey A Lieberman, Alexander L. Miller, 1997 .

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Hans-Jürgen Möller, Siegfried Kasper, Eric Hollander, 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Comparison of quazepam, flunitrazepam and placebo as single-dose hypnotics before surgery

C. Allgulander, E. Wickstrøm, 2004, European Journal of Clinical Pharmacology.

A prospective study of 86 new patients with social anxiety disorder

C. Allgulander, B. Nilsson, Christer Allgulander, 2001, Acta psychiatrica Scandinavica.

Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double‐blind, placebo‐controlled studies

J. Erickson, J. Davidson, M. Pollack, 2008, Human psychopharmacology.

The size and burden of mental disorders and other disorders of the brain in Europe 2010

J. Os, C. Faravelli, L. Fratiglioni, 2011, European Neuropsychopharmacology.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

H. Möller, E. Hollander, D. Stein, 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

ABNORMAL HETEROGENEITY OF SERUM TRANSFERRIN—A NEW DIAGNOSTIC MARKER OF ALCOHOLISM?

C. Allgulander, S. Borg, H. Stibler, 1980, Acta psychiatrica Scandinavica. Supplementum.

Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder

P. Llorca, J. Russell, C. Allgulander, 2011, Human psychopharmacology.

Clinical predictors of completed suicide and repeated self-poisoning in 8895 self-poisoning patients

L. Fisher, C. Allgulander, 2005, European archives of psychiatry and neurological sciences.

[What our patients want and need to know about generalized anxiety disorder].

C. Allgulander, 2007, Revista brasileira de psiquiatria.